Develop permanent birth control solutions (FemBloc and FemChec). Offer artificial insemination solutions (FemaSeed). Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 3.7× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 5% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $2.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 36 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $18.6M against $2.3M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, FEMY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FEMY is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.